Lauro Meneghel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lauro Meneghel has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Amelia Ruffatti
Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani 2, 35128 Padua, Italy
2 shared publicationsAriela Hoxha
Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani 2, 35128 Padua, Italy
2 shared publicationsElena Mattia
Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani 2, 35128 Padua, Italy
2 shared publications- Luca Spiezia
Department of Medicine (DIMED), University of Padua, Padua, Italy
2 shared publications Marny Fedrigo
Chair of Cardiovascular Pathology, Department of Cardiological, Thoracic and Vascular Sciences, University of Padua, Via Giustiniani 2, 35128 Padua, Italy
2 shared publicationsMarta Tonello
Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani 2, 35128 Padua, Italy
2 shared publications
Latest Publications
- 1 June 2015
- Published by Elsevier in Clinica Chimica Acta
- Vol. 446, 201-205
Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome
- 1 June 2015
- Published by Elsevier in Clinica Chimica Acta
- Vol. 446, 201-205
Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome
- 1 January 2015
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 53 (7) , 1083-1089
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method
Fully automated chemiluminescence immunoassays (CLIAs) are emerging technologies for the detection of antiSera were collected from 104 patients with primary APS, 88 seronegative subjects who met the clinical but not the laboratory criteria for APS, and 150 control subjects. IgG/IgM aCL and IgG/IgM anti-β2GPI antibodies were determined in the sera using a CLIA (HemosIL AcuStarCLIA had a significantly lower comparative sensitivity for IgM aCL and IgG/IgM IgG anti-β2GPI antibodies; its comparative specificity was higher with respect to ELISA for IgM aCL and IgM anti-β2GPI antibodies. The two techniques showed a high, significant agreement (p<0.001) and a significant titer correlation (p<0.001). CLIA also detected IgG/IgM aCL and IgG anti-β2GPI antibodies in the seronegative patients. There was a significantly higher prevalence of IgG aCL and IgG anti-β2GPI antibodies (p<0.001 and p=0.01, respectively) in those patients with respect to that in the control population.Despite a lower comparative sensitivity, CLIA showed a higher comparative specificity for some aPL and a good level of agreement and correlation with a homemade ELISA. CLIA also detected some aCL and anti-β2GPI antibodies in the seronegative patients not usually identified by homemade ELISA.
- 1 January 2015
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 53 (7) , 1083-1089
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method
Fully automated chemiluminescence immunoassays (CLIAs) are emerging technologies for the detection of antiSera were collected from 104 patients with primary APS, 88 seronegative subjects who met the clinical but not the laboratory criteria for APS, and 150 control subjects. IgG/IgM aCL and IgG/IgM anti-β2GPI antibodies were determined in the sera using a CLIA (HemosIL AcuStarCLIA had a significantly lower comparative sensitivity for IgM aCL and IgG/IgM IgG anti-β2GPI antibodies; its comparative specificity was higher with respect to ELISA for IgM aCL and IgM anti-β2GPI antibodies. The two techniques showed a high, significant agreement (p<0.001) and a significant titer correlation (p<0.001). CLIA also detected IgG/IgM aCL and IgG anti-β2GPI antibodies in the seronegative patients. There was a significantly higher prevalence of IgG aCL and IgG anti-β2GPI antibodies (p<0.001 and p=0.01, respectively) in those patients with respect to that in the control population.Despite a lower comparative sensitivity, CLIA showed a higher comparative specificity for some aPL and a good level of agreement and correlation with a homemade ELISA. CLIA also detected some aCL and anti-β2GPI antibodies in the seronegative patients not usually identified by homemade ELISA.